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(5/16), speciﬁcity 90.9% (10/11), positive predictive values was
0.81 and negative predictive values 0.47. Overall diagnostic
accuracy resulted 0.55.
Reasons for such disappointing results might be numerous.
First, the retrospective nature of this study is a major confound-
ing factor. A large, multicentric, prospectic study is needed to
validate this score. On the other hand, we believe that our group
of patients is quite different than the one used by authors to
validate the score. Our patients belong to a highly selected subset
of cholestatic infants, addressed even from reference centers for
invasive investigation. This new scoring system seems to work
poorly in this clinical setting, but the paradox is that an effective
score is typically needed in such kind of patients.
Children with a various combination of cholic stools, mild
cholestasis, known risk factors for transient cholestasis, normal
GGT activity and other features not suggestive of BA might be,
in most cases, effectively managed without the need of liver
histology as our results suggest. The overall performance of our
current protocol (3 diagnostic errors out of 64 cases), indeed, is
similar to that of this new scoring system, as claimed in the
paper. However, 48 liver biopsies were spared. Moreover, even
a large, prospective, collaborative study must include some kind
of selection criteria because it might not be ethical to propose a
liver biopsy to all children with ‘‘direct hyperbilirubinemia’’, as
stated in the paper, without further details.
In conclusion, waiting for results of prospective studies, we
believe that we are still waiting for an efﬁcacious and practical
clinical score for BA.
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atresia (BA) score. Second, the small number of patients
(n = 27) in their study carries a very low statistical power of
28.2% at an alpha of 0.05, 2-tailed with 95% CI. This intensiﬁes
the need for validation of the BA score on a sample size larger
than the one in the original article (n = 75) by El-Guindi et al.,
as we already suggested. Third, the historical data they collected
were not pre-designed to evaluate the score parameters before-
hand. For example, the gallbladder length before and after
Table 1. Prevalence of clinical, histological and laboratory items in relation to
the diagnostic score.
BA (n = 16) Non-BA (n = 11)
Clay stool 8 (50%) 1 (9%)
Triangular cord 2 (12.5%) 0
Contractile gallbladder 2 (12.5%) 5 (45.4%)
GL >20.5 mm 0 3 (27 %)
HAD >2.05 mm 4 (25%) 2 (18.2%)
HAD/PVD >0.445 mm 8 (50%) 5 (45.4%)
Hepatic subcapsular flow 1 (6%) 0
gGT >286 14 (87.5%) 6 (54.5 %)
PLT >349,000 11 (68.7%) 5 (45.4%)
DP 16 (100%) 6 (54.5 %)
BP 13 (81.2%) 3 (27 %)
GC 8 (50%) 3 (27 %)
GL, gallbladder length; HAD, hepatic artery diameter; PVD, portal vein diameter;
gGT, gamma glutamyl transpeptidase; PLT, platelets; DP, ductular proliferation;
BP, bile plugs; GC, giant cells.
Letters to the EditorTo the Editor:
We appreciate the interest of Sciveres and colleagues in our
recent study [1] and we would like to respond to their letter
and help them answer the question they raised. Looking thor-
oughly into their retrospective study, many limitations can be
easily pointed out and may account for their disappointment
and poor results. First, the retrospective nature of the study
was not the optimal approach for the validation of the biliary986 Journal of Hepatology 2015 vol. 62 j 975–989
Open access under CC BY-NC-ND license.
liver biopsy relatively high, when compared with other centers
with lower rates [1].
In this concern, we need to emphasize, again, that liver biopsy
is considered as an integral part of the diagnostic workup of neo-
natal cholestasis patients and is strongly encouraged according to
‘‘The Cholestasis Guideline Committee of NASPGN’’ [5], unless
there is a contraindication or when the parents refuse the proce-
dure. Furthermore, liver biopsy can be performed safely, even in
the smallest infants, with sedation and local anesthesia [6]. The
aim of liver biopsy in neonatal cholestasis is, not only to evaluate
the features of biliary outﬂow obstruction, but also essential to
reveal the etiology of the liver disease, and assess ﬁbrosis stage,
which affects the treatment policy.
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feeding was assessed using two timely-spaced ultrasound
reports, which may carry a high fallacy related to different oper-
ators with different judgments.
Another critical point is the evaluation of hepatic subcapsular
ﬂow (HSF), which has the highest value in the BA score (6.735).
Sciveres et al. could detect HSF in only one patient among their
27 patients. In our earlier report [2], we detected HSF in 96.3%
(26/27) of cases in the BA group and in one patient in the
non-BA group. In addition, Lee et al. [3] detected HSF in 100%
(29/29) of cases in the BA group and in 14% (5/35) of the non-BA
group. This raises a doubt about HSF results by Sciveres and
colleagues. Apart from the minimum level of experience needed
for such technique, as we elaborated in our article, this raises
the question of whether the Doppler machine parameters were
set as reported by Lee et al. [3] or El-Guindi et al. [2] for the
detection of HSF. This is not clear in their study.
A further point of concern, although the radiology recordswere
reviewed by a single radiologist, this does not obviate the fact that
the procedureswere performedby different operators and that the
pre-set parametersmight have been different or themachine itself
used in evaluating the patients over this long period might have
varied from one patient to another. All of these may be a source
of biased results and interpretation. For that, we advice Sciveres
and his colleagues to validate the BA score in a prospective
well-designed cohort with pre-set parameters, as reported in
the original report [1]. Furthermore, the use of an appropriate
sample size with acceptable statistical power is essential.
Sciveres et al. suggested that children with a various combina-
tion of normal-colored stool, mild cholestasis, known risk factors
for transient cholestasis, normal gamma glutamyl transpeptidase
activity, and other features not suggestive of BA might be, in most
cases, effectively managed without the need of liver histology.
Here, a question enforces itself. Why would patients with such
criteria of known risk factors and other features not suggestive
of BA be included in a study like ours in the ﬁrst place?
Sciveres and colleagues debated the indication for liver biopsy
in the patients in our study. They mentioned that liver biopsy was
proposed to all children with ‘‘direct hyperbilirubinemia’’ in our
article. This statement can be found nowhere in our article.
Therefore, the allegation is not a true one. Herein, we invite Sci-
veres and his colleagues to review our article with special focus
on the different diagnoses of patients in the non-BA group (in
all of whom liver biopsy was strongly indicated and justiﬁed).
It is well understood that liver biopsy is not indicted for all
cases of neonatal cholestasis, as some etiologies can be managed
without its need. However, the high rate of neonatal cholestasis
patients (200–300 case/year) in our center, including BA patients
(25–35 case/year) [4], makes the number of candidate cases forJournal of Hepatology 2015 vol. 62 j 975–989 987
